|
2012
Jan 17 - GeneWired interviews CEO of ASLAN
2011
Dec 21 - Dynavax and AstraZeneca Agree to Conduct Toxicology Studies for TLR-9 Agonist for Asthma
Nov 3 - ASLAN Pharmaceuticals enters innovative partnership with Bristol-Myers Squibb to license and develop oncology compound
Oct 27 - Dynavax Confirms HEPLISAV Submission Strategies With U.S. FDA and EMA
Oct 25 - Dynavax Data From Two Phase 3 Studies Demonstrate HEPLISAV's Superiority in Immunizing Persons With Diabetes From Hepatitis
Oct 21 - Dynavax and GlaxoSmithKline Expand Their Worldwide Strategic Alliance
Jul 13 - ASLAN inlicenses phase 2 oncology compound from Array Biopharma
May 25 - Dynavax Completes Phase 3 Study of HEPLISAV
Apr 20 - Dynavax Initiates First Human Trial in Lupus Program
Apr 21 - ASLAN completes Series A fundraising providing US$12 million to develop first compounds
Mar 3 - Renovo announces major restructuring
Feb 23 - Dynavax's Two Phase 3 HEPLISAV Trials Cleared by DSMB to Continue to Study Completion
Feb 22 - Dynavax Reports Additional Positive Phase 1B Immunogenicity Data for Hepatitis B Therapy Candidate
Feb 22 - Dynavax Reports New Phase 1a and Phase 1b Data for Universal Flu Vaccine Candidate
Feb 11 - Renovo announes its first EU Phase III trial of JUVISTA in scar revision surgery did not meet its endpoints
Jan 11 - MerLion Signs License Agreement with Alcon to Develop and Commercialize Novel Finafloxacin Otic Product
Jan 4 - Kiadis Pharma signs license agreement with Hospira to commercialize ATIR in Europe and Asia - Partnership would advance innovative stem cell transplant product
2010
2009
|